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Abstract  
 
Background: Arthroscopy was used to observe the clinical effect of liver-softening medicine for treating knee 
osteoarthritis (OA).  
Materials and Methods: Forty knee OA patients with cartilage classifications of Outerbridge grade II, III, or II plus III 
determined via arthroscopy were randomly assigned to a treatment of liver-softening medicine plus glucosamine or a 
control treatment of glucosamine alone. Clinical observation and determination of the comprehensive effect score were 
performed at 60, 120, and 180 days. A second arthroscopy was performed at 180 days.  
Results: Signs and symptoms significantly improved at different time points in the treatment group. The effects in the 
treatment group were better than those in the control group. When analyzing the cartilage during the second 
arthroscopy, no further degeneration was observed.  
Conclusions: After arthroscopic debridement, the treatment of knee OA with liver-softening medicine in conjunction 
with glucosamine is a feasible and effective solution. 
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Introduction 
 
In the treatment of osteoarthritis (OA), the main problems that must be solved are reducing pain, slowing and 
preventing further development of OA, protecting joint function, and improving the quality of life of patients. 
Individualized treatment is necessary (Dubin, 2016; Glyn-Jones et al., 2015; Goldring and Berenbaum, 2015). Specific 
circumstances should be fully considered, such as the risk factors of patients, diseased area, degree of inflammation, 
pain situation, and concomitant diseases (Bloch et al., 2015; Cherian et al., 2016). The treatment principle has remained 
predominantly non-drug therapy combined with drug therapy. Surgical intervention can be performed if necessary. For 
the drug therapy, non-steroidal anti-inflammatory drugs and cartilage-protecting agents are mainly used in Western 
medicine (Kongtharvonskul et al., 2015; Richette et al., 2015).  
However, in traditional Chinese medicine (TCM), OA is known as the Bi syndrome (painful obstruction), which 
means that either the limbs or the joints are suffering from pain and malfunction, and herb therapy has long been a 
standard treatment (Cao et al., 2005). TCM usually initiates therapy using kidney-softening and liver-softening 
supplements based on syndrome differentiation (Han et al., 2010; Li et al., 2011; Li et al., 2014; Mei et al., 2016; Zheng 
et al., 2015). The liver-softening TCM named Yang Xue Ruan Jian (blood-nourishing and hard-softening) capsule 
(YXRJC), which is an extract derived from Bai Shao (radix paeoniae alba), Mu Li (concha ostreae), Qin Jiao (radix 
gentianae macrophyllae) and Gan Cao (radix glycyrrhizae), is a traditional Chinese herb containing mainly paconiflorin 
and gentianine that is used for the symptomatic treatment of inflammation and pain in OA (Cao et al., 2005). YXRJC is 
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the hospital preparation of Shuguang Hospital, which is affiliated with Shanghai University of TCM. There have 
already been clinical studies and applications. Improvements in the symptoms of OA have been confirmed (Cao et al., 
2004; Cao et al., 2004; Shi et al., 1994; Shi et al., 2003). To further study liver-softening TCM, we used knee 
arthroscopy as a means. Arthroscopic debridement and a secondary arthroscopic procedure were performed.  
Arthroscopic debridement includes lavage, loose body removal, osteophytes removal, partial meniscus resection, 
articular surfaces smoothing and adhesion release (Shin and Lee, 2012). Although all of the above contribute to the 
relief of short-term clinical symptoms in the early phases of OA, the further development of the disease could not be 
blocked. The efficacy of arthroscopic debridement has been questioned, especially in arthroscopic management of the 
knee (Pitta et al., 2016). Many studies appraised knee arthroscopy for the treatment of arthritis (Katz et al., 2013; 
Kirkley et al., 2008; Moseley et al., 2002; Steadman et al., 2013). The recommendations regarding the contribution of 
knee arthroscopy to OA are not clear (Marsh et al., 2016). Recent studies identified the role played by arthroscopy in 
the early management of OA (Pitta et al., 2016; Shin and Lee, 2012). With suitable patient choice and reasonable 
expectations being held by both the patient and surgeon, arthroscopy may lead to symptom relief and functional 
improvement in OA patients. 
In our study, combined with the evaluation of clinical effect, a comparative study of liver-softening TCM was 
performed to obtain relevant information to improve the evidence supporting the use of liver-softening TCM for the 
treatment of OA. Simultaneously, the effect of arthroscopic debridement for the treatment of OA was also explored. 
 
Materials and Methods 
General information 
 
This study included 40 patients (24 men and 16 females) with a mean age of 57.2 years (range of 46 to 70 years). 
In accordance with the inclusion criteria and exclusion criteria, the patients exhibited clinical manifestations of knee 
pain and aggravation of pain under the circumstances of walking up and down stairs or long-distance walking, which 
may be accompanied by stiffness, swelling and lower-limb fatigue. 
 
Inclusion criteria 
 
The inclusion criteria were consistent with the diagnostic criteria of Western medicine and TCM syndrome 
differentiation of the knee disease. The diagnostic criteria of Western medicine refer to the diagnostic criteria for OA of 
the knee in the “OARSI guidelines for the non-surgical management of knee OA,” developed by Osteoarthritis 
Research Society International (OARSI) (McAlindon et al., 2014). TCM syndrome differentiation is based on TCM 
syndrome differentiation and treatment of knee paralysis (knee OA) developed by the State Administration of TCM 
(Huang et al., 2014). The radiographic severity was grade III or less and was quantified using an overall severity grade 
(Kellgren and Lawrence grade (KL)) (Altman et al., 1995). The grades of cartilage as determined via recent 
arthroscopy were grade II, grade III, or grade II plus III according to the Outerbridge classification system (Outerbridge, 
1961). Informed consent was granted by the patients. 
 
Exclusion criteria 
 
The exclusion criteria included pregnant and lactating women; patients under 40 years old or more than 70 years 
old; patients with YXRJC or a glucosamine sulfate capsules allergy, primary synovitis, bone tuberculosis, a bone tumor, 
pigment villonodular synovitis, serious cardio cerebral vascular and hematopoietic system disease, mental disease, 
abnormal liver function, a history of skin allergies, a history of long-term use of other drugs that may influence the 
effect and safety; and patients who participated in other clinical trials within three months. 
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Test scheme 
 
A randomized, double-blind controlled clinical trial, was performed. Forty cases were selected and randomly 
divided into 2 groups, with 20 cases in each group. There was no significant difference between the two groups in terms 
of age or disease course. In the treatment group, 2 capsules of glucosamine sulfate and 3 YXRJCs were taken by mouth 
3 times daily. In the control group, 2 capsules of glucosamine sulfate and 3 starch capsules were taken by mouth 3 
times daily. The glucosamine sulfate capsule (Yi Suojia), 0.314 g*24 / box, was produced by Zhejiang Hisun 
Pharmaceutical Co., Ltd., Zhejiang Province, China under the state medical permit No. H20041316. The YXRJC, 0.35 
g*60 / box, was a hospital preparation produced by Shuguang Hospital, which is affiliated with Shanghai University of 
TCM, with the drug approval number of the Shanghai medicine system Z04100932. Each capsule contained 0.21 g 
drugs and 0.14 g excipients. Arthroscopic debridement was performed on all patients before they were enrolled. In the 
operation, the cartilage with the Outerbridge grade II, grade III, or grade II plus III could be observed and recorded. 
The degenerative cartilage was not treated. Anteroposterior and lateral X-ray films of the standing position knee joint 
were taken and properly graded using the KL grade system. Patients were required to complete the Western Ontario and 
McMaster Universities Arthritis Index (WOMAC) questionnaire before the operation. All the patients took the oral 
medicine for 180 days. At days 60, 120 and 180, patients were requested to participate in follow-up visits and complete 
the WOMAC questionnaire. The arthroscopic procedure was performed again at day 180.  
 
Concomitant therapy and medication 
 
Massage, acupuncture and Chinese herbal patch therapy were used simultaneously in both groups. Massage was 
completed according to the following methods. First, relaxing the quadriceps femoris, pointing, kneading and 
strumming the start and end points of the muscles around the knee joint were performed in a supine position. Pointing 
and pressing the double eyes of the knee and patellofemoral joint space while stretching and flexing the knee followed. 
Finally, pointing and kneading the points of Weizhong, Chengshan, Yinmen, and Kunlun were performed in the prone 
position. The acupuncture points were mainly the medial knee eye, medial and superior knee eye, exterior knee eye, 
and exterior and superior knee eye. The needle penetrated 1-1.5 inch into the joint cavity. The warm needling method 
was also used. A herbal patch with the function of promoting blood circulation to relieve pain was selected. All patients 
were prohibited from using oral nonsteroidal anti-inflammatory drugs or corticosteroid injections. 
 
Assessment of therapeutic effects 
 
The methods comprised a comparison of the Outerbridge grades of cartilage under arthroscopy and WOMAC 
scores before and after the treatment. The WOMAC subscales include pain (5 items), stiffness (2 items) and physical 
functioning (17 items). Each item is scored from 0 to 4, yielding a score range of 0-20, 0-8 and 0-68 for the pain, 
stiffness and physical functioning subscales, respectively (Bellamy et al., 1988). In addition, comprehensive evaluation 
of the effect was performed at 180 days after the treatment, including a self-evaluation of the effect by the patients 
using a five-point Likert score (5 points method, 0: very poor; 1: poor; 2: general; 3: good; 4: very good) and a 
therapeutic effect evaluation by the doctors using a five-point Likert score (5 points method, 0: very poor; 1: poor; 2: 
general; 3: good; 4: very good) (Likert and Rensis, 1932). 
 
Statistical evaluation 
 
The data analysis was performed using the SAS version 6.12 statistical software package to perform two-factor 
mixed-design analysis of variance. 
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Results 
Comparison of the two groups after treatment with arthroscopic cartilage grading 
  
The degenerative cartilage grading under arthroscopy before and after the treatment revealed that no changes 
occurred in the recorded cartilage grading for both the treatment group and control group. The results meant that there 
was no further aggravation of cartilage degeneration. 
 
Comparison of the WOMAC scores of the two groups at different time points 
 
The analysis of variance of repeated-measures data in a two-factor mixed design (see Table 1 and Table 2) 
revealed that the main effects of the within-subject factor (time) on WOMAC total score, pain score, stiffness score and 
physical function score were statistically significant (P<0.05). The main effects of the between-group factor (Group) on 
the WOMAC total score, stiffness score and physical function score were statistically significant (P<0.05). The main 
effects on the WOMAC pain score were not statistically significant (P>0.05). Simple effect analysis results (see Table 3) 
revealed that comparing the WOMAC total score, pain score, stiffness score and physical function score of the two 
groups, there were no statistically significant (P>0.05) differences between before treatment and at the end of 60 days 
of treatment. The WOMAC total score, pain score, stiffness score and physical function score of the treatment group 
were significantly less than those of the control group (P<0.05) at the end of both 120 and 180 days of treatment. The 
results indicated that the WOMAC total score, pain score, stiffness score and physical function score of the two groups 
decreased gradually and significantly as the treatment time prolonged. The long-term effect of the treatment group was 
superior to that of the control group. 
 
Table 1: Main effects of the within-subject factor (time) (Greenhouse-Geisser correction) 
Indicator Source of 
Difference 
Sum of 
Squares of 
Deviations 
Degree of 
Freedom 
Mean 
Square 
F value P 
value 
WOMAC total score Time 69495.469 1.396 49 772.312 423.222 0.000 
 Time*Group 3717.469 1.396 2 662.433 22.639 0.000 
 Error 6239.813 53.058 117.603   
WOMAC pain score Time 5479.450 1.872 2926.482 381.843 0.000 
 Time*Group 218.750 1.872 116.831 15.244 0.000 
 Error 545.300 71.150 7.664   
WOMAC stiffness 
score 
Time 1174.850 1.267 927.273 257.910 0.000 
 Time*Group 77.550 1.267 61.208 17.024 0.000 
 Error 173.100 48.146 3.595   
WOMAC physical 
function score 
Time 24235.050 1.676 14457.824 211.892 0.000 
 Time*Group 1464.725 1.676 873.806 12.806 0.000 
 Error 4346.225 63.698 68.232   
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Table 2: Main effects of the between-group factor (Group)) 
Indicator Source of 
Difference 
Sum of 
Squares of 
Deviations 
Degree 
of 
Freedom 
Mean 
Square 
F value P value 
WOMAC total score Group 3696.006 1 3696.006 8.695 0.005 
 Error 16152.438 38 425.064   
WOMAC pain score Group 211.600 1 211.600 1.595 0.214 
 Error  38    
WOMAC stiffness score Group 202.500 1 202.500 4.275 0.046 
 Error 1799.900 38 47.366   
WOMAC physical 
function score 
Group 1030.225 1 1030.225 24.235 0.000 
 Error 1615.375 38 42.510   
 
Table 3: Comparison of the WOMAC scores of the two groups at different time points（ x ±S）Remarks: For the same 
group, comparison of time points with different right superscript letters, P<0.05. For the same group, comparison of 
groups with same right superscript letters (*#), P>0.05; comparison of groups with different right superscript letters 
(*#), P<0.05. 
Group n 
WOMAC total score  WOMAC pain score 
Baseline 60d  120d  180d   Baseline 60d  120d  180d  
Control  20 129.3±18.6a* 108.5±12.7b* 100.5±7.0c* 83.9±5.2d*  
28.3±7.6 
a* 
22.1±6.8 
b* 
19.5±5.2 
c* 
15.3±4.0 
d* 
Treatment 20 130.9±19.3a* 106.5±12.5b* 83.5±6.9c# 62.7±4.3d#  
29.1±6.2 
a* 
21.2±7.3 
b* 
15.2±6.5 
c# 
10.4±3.4 
d# 
Group n 
WOMAC stiffness score  WWOMAC physical function score 
Baseline 60d  120d  180d  Baseline 60d 120d  180d  
Control  20 14.6±4.6 a* 11.0±4.1 b* 10.7±3.6 c* 8.4±2.1d*  
86.4±7.8 
a* 
75.4±6.7 
b* 
70.3±4.9 
c* 
60.2±3.4 
d* 
Treatment 20 13.2±4.2 a* 10.6±3.6 b* 7.5±3.4 c# 4.4±2.5d#  
88.6±9.7 
a* 
74.7±6.5 
b* 
60.8±4.5 
c# 
47.9±2.5 
d# 
 
Comparisons of the effect self-evaluated by patients and the therapeutic effect evaluated by doctors between the 
two groups 
 
Based on a t-test of two sample means, the self-evaluated effect scores in the treatment group (3.55±0.51) were 
significantly better than those in the control group (2.55±0.68) (P<0.05). The therapeutic effect scores in the treatment 
group (3.65±0.49) were also significantly better than those in the control group (2.85±0.49) (P<0.05). 
 
Discussion  
 
In aging populations, effective treatment of knee OA in the elderly is one of the main research topics (Bannuru et 
al., 2015; Gelber, 2015). This study is based on the arthroscopic treatment of knee OA with TCM. The study both 
observed the effect of arthroscopy on knee OA and used arthroscopy to evaluate the effect of the liver-softening TCM 
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named YXRJC. 
Arthroscopic debridement, as a minimally invasive technique, has the advantages of open surgery in the treatment 
of knee OA because of the small operation wound and fast recovery. Arthroscopic debridement has become the 
"transfer station" of the conservative treatment of knee OA and joint replacement surgery, which have been paid 
increasingly more attention by clinicians (Katz et al., 2014). However, arthroscopic debridement is a palliative 
procedure to improve symptoms and delay progression of the disease. Although it has been used in clinical practice for 
several decades, and the effect is significant for some patients, there has been a new debate about whether arthroscopic 
debridement is effective in recent years (Adams, 2014; Krych et al., 2013; Siparsky et al., 2007). The American College 
of Rheumatology (ACR), American Academy of Orthopaedic Surgeons (AAOS), and Osteoarthritis Research Society 
International (OARSI) have published OA treatment guidelines over the past few years (Katz et al., 2014). The 
guidelines developed by professional organizations and insurance companies did not encourage use of arthroscopic 
debridement to treat knee OA. The role of arthroscopy for OA treatment is still a controversial issue. More recent 
evidence suggests that properly selected patients may benefit from arthroscopy (Pitta et al., 2016; Shin and Lee, 2012). 
Built on the review of clinical studies, the recommended indications for knee arthroscopic debridement are 
hydroarthrosis, localized joint line tenderness, acute or aggravating catching or locking, development or aggravation of 
symptoms related to a specific injury mechanism, loose body, and early stage degenerative arthritis. Currently, there is 
still controversy regarding whether arthroscopic debridement has a placebo effect. We believe that OA is a degenerative 
change with age that is inevitable. Debridement of OA can improve pain symptoms in patients, but it is not possible to 
solve the fundamental problem of joint degeneration. Therefore, we performed a selective and limited cleaning during 
the operation to reduce the joint disturbance. The flushing of the joint cavity was enhanced to reduce inflammatory 
factors such as interleukins and prostaglandins. We cleaned the stripped cartilage debris, repaired the articular cartilage 
and meniscus, resected the function-affected osteophytes, and released the patellar retinaculum to reduce the pressure 
of the patellofemoral articular surface and improve the joint function. Simultaneously, supportive physical therapy and 
drug therapy were applied to enhance the long-term curative effect. 
Glucosamine is one of the disease-modifying osteoarthritis drugs (DMOADs) with different and even 
contradictory treatment conclusions. Experts views and guidelines are not yet consistent. The European League Against 
Rheumatism (EULAR) Recommendations 2003 (Jordan et al., 2003) and OARSI Recommendations 2010 (Zhang et al., 
2010) both recommended glucosamine as a DMOAD to improve OA symptoms. In 2012, the ACR guidelines 
(Hochberg et al., 2012) did not recommend glucosamine because they noted that glucosamine is not a prescription drug 
in the USA but rather only a dietary supplement, whose quality has not been evaluated by the Food and Drug 
Administration (FDA). The updated OARSI guidelines 2014 (McAlindon et al., 2014) stated that the recommendation 
of glucosamine was uncertain for symptom relief and not appropriate for disease modification. The main reason was 
the consideration by some experts of the lack of sufficient evidence-based research into the effects of glucosamine as a 
non-prescription drug. In addition, there were obvious distinctions between the efficacy in clinical practice and in 
rigorously designed clinical studies. Experts also note that "uncertain" does not mean a disagreement with the 
prescription of glucosamine. However, an algorithm recommendation in 2014 of the European Society for Clinical and 
Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) (Bruyère et al., 2014) stated that glucosamine sulfate 
was superior to the placebo in the treatment of pain and functional impairment with the effect size of 0.27 (95% CI: 
0.12-0.43) on pain and 0.33 (95% CI: 0.17-0.48) on function. Long-term prescription glucosamine sulfate might delay 
joint structure changes, suggesting potential benefit beyond symptom control when used early in the management of 
OA. In addition to its efficacy record, glucosamine sulfate is a safe medication with no difference in adverse effects 
compared with placebo, which strengthens the argument for its use as a chronic background treatment. Because ethics 
does not allow using a placebo alone as a control in clinical trials with periods of 6 months or more, we prescribed 
glucosamine in both the treatment and control groups. YXRJC is a prescription of TCM, and its mechanism is different 
from that of glucosamine. The purpose of this study was not to investigate glucosamine but rather to determine the 
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efficacy of and adverse reactions to YXRJC on the basis of glucosamine treatment.  
Professor Shi Yin-yu (Cao et al., 2006) believes that knee OA is a root of wilting and tip of impediment, 
coexistence of impediment and wilting. Under the guidance of this thought for the treatment of OA, the kidney and 
liver should be soft, and nourishing blood is also needed. The ingredients of liver-softening TCM named YXRJC are 
Bai Shao (radix paeoniae alba), Mu Li (concha ostreae), Qin Jiao (radix gentianae macrophyllae) and Gan Cao (radix 
glycyrrhizae); these serve the function of nourishing and activating blood, and softening hard and dredging collaterals. 
Bai Shao belongs to the liver meridian, with the actions of preserving Yin to nourish blood, soften the liver, and relieve 
pain. Mu Li belongs to the liver, kidney and lung meridian, with the actions of calming the liver and subduing Yang, 
quieting the spirit with heavy settlers, dissolving hard lumps, and inducing astringency. Qin Jiao belongs to the liver, 
stomach and gallbladder meridian, with the actions of expelling wind, removing dampness, relaxing the muscles and 
stimulating blood circulation. Gan Cao reconciles other drugs. Past studies have found that the liver-softening medicine 
has a better effect on delaying the degradation of cartilage in the early and late stages of OA (Li et al., 2011; Li et al., 
2014; Zheng et al., 2015). The liver-softening medicine also has certain inhibitions on synovitis (Han et al., 2010; Mei 
et al., 2016). It can promote the synthesis of DNA in cartilage cells, collagen and protein of the cartilage (Chen et al., 
2014; Yuan et al., 2012). It has a protective effect on cartilage during the course of OA. One of the mechanisms for the 
prevention and treatment of OA may be to reduce the COMP expression of cartilage matrix protein in the synovial 
tissue, which can delay the pathological process of OA (Cao et al., 2007; Feng et al., 2001; Shi et al., 2007; Zhang et al., 
2008). Treatment of OA with liver-softening medicines has been supported by some academic research and aroused 
extensive attention (Chen et al., 2014; Yuan et al., 2012). This study found that at the second arthroscopic observation 
of the Outerbridge grade II or III degenerative cartilage, there was no further aggravation of degeneration in either the 
YXRJC and glucosamine sulfate group or pure glucosamine sulfate group, which indicates that both YXRJC and 
glucosamine sulfate can postpone cartilage degeneration. The WOMAC total score further indicated that the 
liver-softening medicine YXRJC had a good clinical curative effect in the medium term, especially at 120 days and 180 
days. 
In summary, treatment of knee OA with arthroscopic surgery combined with the liver-softening medicine YXRJC 
and glucosamine sulfate is a feasible and effective method. Of course, this study is limited by the small number of cases. 
The main reason for this small number is the patients’ low rate of acceptance of the second arthroscopic surgery. In 
addition, OA patients with the KL classification standard grade IV and above were not included in this study. We 
believe that in the condition of the existing large osteophytes and joint space narrowing in the KL grade IV or above, 
knee arthroscopic debridement is unable to remove the large intraarticular osteophytes with a good therapeutic effect. 
Additionally, there were no observations and analysis of Outerbridge grade IV cartilage under arthroscopy in this study. 
Outerbridge grade IV cartilage has deep cortical degeneration, full-thickness cartilage defect, and subchondral bone 
exposure. In this case, the effect of conventional arthroscopic debridement, drilling, micro fracture and grinding is often 
poor. For such patients, drug treatment should be based on anti-inflammatory and analgesic drugs. Total knee 
arthroplasty is usually the best choice. 
 
Conclusions 
 
After arthroscopic debridement, treatment of knee OA with liver-softening medicine associated with glucosamine 
is a feasible and effective solution. The treatment received satisfactory mid-term curative results. The application of the 
liver-softening medicine YXRJC reflects that TCM combined with modern medicine has bright prospects. 
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